Form 4: AN2 Therapeutics CSO Sells Shares for Tax Obligations

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, sold 765 shares of common stock to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, Inc. (ANTX), reported a transaction involving the sale of 765 shares of common stock.
• The sale occurred on November 4, 2025, at a price of $1.14 per share.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on the same date.
• Following this transaction, Mr. Prior beneficially owns 65,548 shares of common stock.
• This beneficial ownership includes 10,125 RSUs that will vest annually over four years, starting from November 4, 2024.
• It also includes an additional 12,031 RSUs set to vest on January 1, 2026, contingent on continued service to the company.
• The reported beneficial ownership also reflects the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.

Sentiment

Score: 6

Explanation: The filing details a routine, non-discretionary sale of shares to cover tax obligations from RSU vesting, which is a common occurrence for executives. The simultaneous purchase of shares through an ESPP and significant remaining RSU holdings suggest continued alignment and confidence, preventing a negative sentiment despite the sale.

Positives

• The Chief Strategy Officer purchased 5,000 shares under the company's Employee Stock Purchase Plan on September 30, 2025, indicating continued investment and confidence.
• Despite the sale for tax purposes, the officer retains significant beneficial ownership of 65,548 shares, including substantial future RSU vesting, aligning management interests with shareholders.

Negatives

• The sale of 765 shares, even for tax withholding, represents a reduction in the officer's direct common stock holdings.

Future Outlook

The Chief Strategy Officer has significant future equity compensation vesting, including 10,125 RSUs vesting annually over four years from November 4, 2024, and 12,031 RSUs vesting on January 1, 2026, all subject to continued service to the company.

Industry Context

This transaction is a routine insider filing common in the biotechnology and pharmaceutical industry, where executives often receive equity compensation. Sales to cover tax withholding obligations upon RSU vesting are standard practice and generally not indicative of a change in management's outlook on the company's prospects.

Comparison to Industry Standards

• The transaction represents a routine tax-related sale, which is a common occurrence for executives in the biotechnology and pharmaceutical industry who receive equity compensation in the form of Restricted Stock Units (RSUs).
• This type of transaction is not typically indicative of a change in management's outlook on the company's prospects, unlike discretionary sales, and aligns with standard practices for managing equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact as the transaction is routine and non-discretionary, not signaling a change in management's confidence.
• Employees: No direct impact mentioned beyond the Chief Strategy Officer's equity compensation.

Next Steps

• Continued vesting of 10,125 RSUs annually over four years from November 4, 2024.
• Vesting of 12,031 RSUs on January 1, 2026.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of a small number of shares by the Chief Strategy Officer solely to cover tax withholding obligations related to RSU vesting. This is a routine event and does not signal a change in the officer's confidence or the company's fundamentals. Furthermore, the officer also purchased shares through an Employee Stock Purchase Plan and retains substantial beneficial ownership, including future RSU vesting. Therefore, this filing does not provide new information that would warrant a change in investment recommendation, maintaining a 'hold' stance.

Keywords

AN2 Therapeutics, ANTX, Form 4, insider transaction, stock sale, RSU, restricted stock units, employee stock purchase plan, Stephen David Prior, Chief Strategy Officer